secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001104659-24-108914
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco presents Zenrelia study showing similar serologic response; approved in Canada
--------------------------------------------------------------------------------

- Study presented at ISCAID: 68 beagles given ilunocitinib at 1X or 3X label dose for 56 days; protective titer levels post-booster similar to control group.
- No serious adverse events observed; supports safety of Zenrelia concurrent with core booster vaccinations including rabies.
- Zenrelia (ilunocitinib) received regulatory approval in Canada; further details on Health Canada Drug Product Database.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924108914/0001104659-24-108914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924108914/tm2425466d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-108914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer